TMCnet News
Research and Markets: Bio-Europe 2014 Cancer Drug Pipeline Update 2015Research and Markets (http://www.researchandmarkets.com/research/b5qhf2/bioeurope_2014) has announced the addition of the "Bio-Europe 2014 Cancer Drug Pipeline Update 2015" report to their offering. BIO-Europe 2014 (3rd to 5th November) is Europe's largest biotech partnering conference and is of huge significance for the oncology industry. In fact, the author can reveal that companies participating at this years event are responsible for slightly more than 40% of the global oncology pipeline under active development. To reflect this importance, the analyst team identifies 264 participting companies plus partners who are today actively developing 1572 cancer drugs in 4673 developmental projects in cancer across 625 different targets. In addition, there are 20 suspended drugs and another 784 drugs where development has been ceased. We are pleased to introduce the BIO-Europe 2014 Cancer Drug Pipeline Update: For busy executives within Pharma, Biotech and Investment companies who know they need to stay on top of the developmental environment in their field. You get detailed, world-wide drug pipeline information, delivered in an unbiased and independent pipeline progress analysis for each identified drug. Whether or not you are attending BIO-Europe 2014, you can get long term benefits from the BIO-Europe 2014 Cancer Drug Pipeline Update: Access the conference's entire oncology portfolio and identify the companies and drugs of most value to you. Pipeline Breakdown According to Number of Drugs
For more information visit http://www.researchandmarkets.com/research/b5qhf2/bioeurope_2014
|
